INTEGRATE II is a phase III international multi-centre clinical trial to determine whether Regorafenib is effective in prolonging survival in patients with Advanced Gastro-Oesophageal Carcinoma. 

See ANZCTR for full trial details >

 

Trial Summary:

The aim of the study is to further examine the findings of the previous INTEGRATE clinical trial. The purpose of INTEGRATE II is to determine whether Regorafenib is effective in prolonging survival in patients with Advanced Gastro-Oesophageal Carcinoma (AGOC).

Supported By:

AGITG

Eligibility:

Adults (18 years or over) with metastatic or locally recurrent gastro-oesophageal cancer

Registration ID:

ACTRN12616000420448

Participation:

International

Australian Lead Group:

AGITG

Status:

Open

Activation Date:

23/06/2016

Chairs:

Nick Pavlakis, David Goldstein

Contact:

INTEGRATEII@ctc.usyd.edu.au